News · 26 weeks76+233%
2026-03-012026-08-23
Mix3390d
- Insider22(67%)
- SEC Filings5(15%)
- Other4(12%)
- Earnings2(6%)
Latest news
25 items- INSIDERChief Financial Officer Chen Yajing sold $7,020 worth of American Depositary Shares (260 units at $27.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.72% to 35,635 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChief Financial Officer Chen Yajing converted options into 1,250 units of American Depositary Shares and covered exercise/tax liability with 427 units of American Depositary Shares, increasing direct ownership by 2% to 35,895 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- PRZai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisStudy met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and argenx ((Euronext &, NASDAQ:ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met
- INSIDERDirector Lis William sold $212,650 worth of American Depositary Shares (8,506 units at $25.00) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 41,931 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChief Financial Officer Chen Yajing sold $15,475 worth of American Depositary Shares (619 units at $25.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 35,072 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- SECSEC Form 144 filed by Zai Lab Limited144 - Zai Lab Ltd (0001704292) (Subject)
- SECSEC Form 10-Q filed by Zai Lab Limited10-Q - Zai Lab Ltd (0001704292) (Filer)
- SECZai Lab Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Zai Lab Ltd (0001704292) (Filer)
- PRZai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate UpdatesThe Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026 Global Phase 1 data for zocilurtatug pelitecan (zoci) in combination with a PD-L1 inhibitor in first-line SCLC to be presented at ESMO 2026; planned initiation of a registrational Phase 3 study later this year Registrational Phase 3 DLLEVATE study evaluating zoci in second-line plus SCLC remains on track, with enrollment expected to be completed in the first half of 2027, supporting a potential U.S. accelerated approval submission in 2027 Global Phase 1/1b study of ZL-1503, a potential first-in-
- PRU.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need - U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary NECs from the European Medicines Agency, reinforcing zoci’s first-in-class potential in a range of NECs Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for the treatment of neuroendocrine carcinomas (NECs). NECs are aggressive malign
- PRZai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026- Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred): htt
- INSIDERDirector Gaynor Richard bought $33,071 worth of American Depositary Shares (1,736 units at $19.05), increasing direct ownership by 2% to 80,737 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying converted options into 29,048 units of American Depositary Shares and covered exercise/tax liability with 11,431 units of American Depositary Shares, increasing direct ownership by 1% to 1,221,401 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying sold $130,220 worth of American Depositary Shares (7,026 units at $18.53) and converted options into 17,970 units of American Depositary Shares, increasing direct ownership by 0.92% to 1,203,784 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChief Legal Officer Edmondson Frazor Titus Iii converted options into 14,600 units of American Depositary Shares and sold $71,642 worth of American Depositary Shares (4,103 units at $17.46), increasing direct ownership by 53% to 30,346 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying converted options into 58,800 units of American Depositary Shares and sold $428,545 worth of American Depositary Shares (24,543 units at $17.46), increasing direct ownership by 3% to 1,192,840 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChief Financial Officer Chen Yajing converted options into 6,250 units of American Depositary Shares and sold $39,532 worth of American Depositary Shares (2,264 units at $17.46), increasing direct ownership by 13% to 35,691 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Lis William sold $127,354 worth of American Depositary Shares (7,040 units at $18.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 50,437 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Wirth Peter was granted 22,371 units of American Depositary Shares, increasing direct ownership by 6% to 416,121 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Diekman John D was granted 22,371 units of American Depositary Shares, increasing direct ownership by 22% to 122,140 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Morrison Scott W was granted 22,371 units of American Depositary Shares, increasing direct ownership by 65% to 56,904 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Moulder Leon O Jr was granted 22,371 units of American Depositary Shares, increasing direct ownership by 31% to 94,973 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Leung Nisa was granted 22,371 units of American Depositary Shares, increasing direct ownership by 30% to 96,297 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Gaynor Richard was granted 22,371 units of American Depositary Shares, increasing direct ownership by 40% to 79,001 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Vounatsos Michel was granted 22,371 units of American Depositary Shares, increasing direct ownership by 44% to 72,787 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
ZLAB FAQ
7 questionsWhat does Zai Lab Limited do?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer...Where does ZLAB stock trade?
Zai Lab Limited (ZLAB) is listed on NASDAQ.What sector and industry is ZLAB in?
Zai Lab Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zai Lab Limited go public?
Zai Lab Limited (ZLAB) completed its IPO in 2017.What are analysts saying about ZLAB?
Zai Lab Limited has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2025-08-25. Recent price targets range from $3610.00 to $4750.00.What companies are similar to ZLAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZLAB side-by-side with any of them on Quantisnow.How can I track ZLAB on Quantisnow?
Quantisnow aggregates Zai Lab Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZLAB to receive live email and push alerts on every new disclosure.